Johnson & Johnson (JNJ: NYSE)
$101.08 n/a | n/a%
04/24/15 - 04:00 PM ET
|REVENUE (Trailing 12 Quarters)|
|EARNINGS PER SHARE (Trailing 12 Quarters)|
|DIVIDENDS (Trailing 12 Quarters)|
Portfolios with JNJ
- Portfolio NameUser Type
- ProJohn Hussman - Hussman Stra...
- ProRenaissance Technologies
- ProKen Fisher - Fisher Investm...
- ProJoel Greenblatt - Gotham Ca...
- ProJames Barrow - Barrow Hanle...
- ProDonald Yacktman - Yacktman ...
- ProBrian Rogers - T. Rowe Pric...
- ProPrem Watsa - Fairfax Financ...
- ProAdage Capital
- ProAcropolis Investment Manage...
Latest JNJ Headlines from TheStreet
- Today's Top Performers In Drugs 04.24.15 | 01:04 pm
- 15 'Sustainable' Companies Not Named Apple to Buy Right Now 04.22.15 | 04:04 pm
- 3 Stocks Pushing The Drugs Industry Higher 04.20.15 | 01:04 pm
- Jim Cramer's 'Mad Money' Recap: Don't Bet Against This Market 04.15.15 | 08:04 pm
- Jim Cramer's 'Mad Money' Recap: 6 Positive Things You Should Keep in Focus 04.14.15 | 08:04 pm
- Johnson And Johnson (JNJ) Earnings Report: Q1 2015 Conference Call Transcript 04.14.15 | 01:04 pm
- Dow Jones (DJIA) Today: Johnson & Johnson (JNJ) Higher 04.14.15 | 12:04 pm
- Johnson & Johnson (JNJ) Stock Climbing Today on Better Than Expected First Quarter Earnings 04.14.15 | 08:04 am
- IBM Adds Apple, Others to Watson Partnership, Unveils Watson Health Cloud 04.13.15 | 05:04 pm
- Dow Jones (DJIA) Today: Johnson & Johnson (JNJ) Lower 04.13.15 | 01:04 pm
Press Releases for JNJ
- Johnson & Johnson Announces Dividend Increase Of 7.1% - PR Newswire 04.23.15 | 10:04 am
- Johnson & Johnson To Host Pharmaceutical Business Review - PR Newswire 04.20.15 | 02:04 pm
- Janssen Pharmaceuticals, Inc. Completes Divestiture Of U.S. License Rights To NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) Extended-release Tablets And NUCYNTA® (tapentadol) Oral Solution To Depomed, Inc. - PR Newswire 04.02.15 | 04:04 pm
- Johnson & Johnson To Webcast Annual Meeting Of Shareholders - PR Newswire 03.27.15 | 08:03 am
- Johnson & Johnson To Host Investor Conference Call On First-Quarter Results - PR Newswire 03.17.15 | 11:03 am
- Johnson & Johnson Announces Strategic Investment Alliance To Combat Dementia Globally - PR Newswire 03.17.15 | 04:03 am
- Johnson & Johnson Announces Binding Offer From Cardinal Health To Acquire Cordis - PR Newswire 03.02.15 | 07:03 am
- Johnson & Johnson Announces Formation Of New Health And Wellness Platform Designed To Transform Health Care Delivery And Improve The Patient Experience - PR Newswire 02.26.15 | 08:02 am
- Johnson & Johnson Announces Patent And Trademark Office Action Related To REMICADE® - PR Newswire 02.12.15 | 02:02 pm
- Dr. Paul Janssen Award For Biomedical Research Issues 2015 Call For Nominations - PR Newswire 01.21.15 | 09:01 am
Partner Headlines for JNJ
- DepoMed Set To Grow On 'Transformative' Nucynta Deal - Investor's Business Daily 04.23.15 | 04:04 pm
- Johnson & Johnson added to short-term buy list at Deutsche Bank - The Fly 04.20.15 | 06:04 am
- Johnson & Johnson valuation appears attractive, says Wells Fargo - The Fly 04.15.15 | 08:04 am
- Cramer Remix: This company's worth double - CNBC 04.14.15 | 07:04 pm
- Cramer: Big market positives that can't be ignored - CNBC 04.14.15 | 06:04 pm
- J&J Earnings Beat Estimates; Guidance Mixed - Investor's Business Daily 04.14.15 | 05:04 pm
- Four trades to go before Tuesday's close - CNBC 04.14.15 | 03:04 pm
- Small spine names have positive read through from J&J results, says Wells Fargo - The Fly 04.14.15 | 02:04 pm
- Cyclacel Pharmaceuticals, Inc. (CYCCP) Ex-Dividend Date Scheduled for April 15, 2015 - NASDAQ 04.14.15 | 01:04 pm
- J&J earnings beat despite THIS factor - CNBC 04.14.15 | 09:04 am